KNSA
Price
$28.80
Change
+$0.71 (+2.53%)
Updated
Jul 14 closing price
Capitalization
2.1B
14 days until earnings call
NTLA
Price
$11.36
Change
-$0.59 (-4.94%)
Updated
Jul 15, 04:17 PM (EDT)
Capitalization
1.24B
16 days until earnings call
Interact to see
Advertisement

KNSA vs NTLA

Header iconKNSA vs NTLA Comparison
Open Charts KNSA vs NTLABanner chart's image
Kiniksa Pharmaceuticals International
Price$28.80
Change+$0.71 (+2.53%)
Volume$406.73K
Capitalization2.1B
Intellia Therapeutics
Price$11.36
Change-$0.59 (-4.94%)
Volume$400
Capitalization1.24B
KNSA vs NTLA Comparison Chart in %
Loading...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KNSA vs. NTLA commentary
Jul 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KNSA is a Hold and NTLA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 15, 2025
Stock price -- (KNSA: $28.80 vs. NTLA: $11.95)
Brand notoriety: KNSA and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KNSA: 49% vs. NTLA: 56%
Market capitalization -- KNSA: $2.1B vs. NTLA: $1.24B
KNSA [@Biotechnology] is valued at $2.1B. NTLA’s [@Biotechnology] market capitalization is $1.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $305.86B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KNSA’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • KNSA’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both KNSA and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KNSA’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 6 bullish TA indicator(s).

  • KNSA’s TA Score: 4 bullish, 5 bearish.
  • NTLA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than KNSA.

Price Growth

KNSA (@Biotechnology) experienced а +3.04% price change this week, while NTLA (@Biotechnology) price change was +16.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.48%. For the same industry, the average monthly price growth was +21.25%, and the average quarterly price growth was +31.32%.

Reported Earning Dates

KNSA is expected to report earnings on Nov 04, 2025.

NTLA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+10.48% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNSA($2.1B) has a higher market cap than NTLA($1.24B). KNSA YTD gains are higher at: 45.602 vs. NTLA (2.487). KNSA has higher annual earnings (EBITDA): -14.23M vs. NTLA (-530.8M). NTLA has more cash in the bank: 504M vs. KNSA (268M). KNSA has less debt than NTLA: KNSA (9.92M) vs NTLA (119M). KNSA has higher revenues than NTLA: KNSA (481M) vs NTLA (45.6M).
KNSANTLAKNSA / NTLA
Capitalization2.1B1.24B170%
EBITDA-14.23M-530.8M3%
Gain YTD45.6022.4871,833%
P/E Ratio164.54N/A-
Revenue481M45.6M1,055%
Total Cash268M504M53%
Total Debt9.92M119M8%
FUNDAMENTALS RATINGS
KNSA vs NTLA: Fundamental Ratings
KNSA
NTLA
OUTLOOK RATING
1..100
517
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
30
Undervalued
PROFIT vs RISK RATING
1..100
76100
SMR RATING
1..100
9097
PRICE GROWTH RATING
1..100
4240
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (30) in the Biotechnology industry is somewhat better than the same rating for KNSA (84) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew somewhat faster than KNSA’s over the last 12 months.

KNSA's Profit vs Risk Rating (76) in the Pharmaceuticals Major industry is in the same range as NTLA (100) in the Biotechnology industry. This means that KNSA’s stock grew similarly to NTLA’s over the last 12 months.

KNSA's SMR Rating (90) in the Pharmaceuticals Major industry is in the same range as NTLA (97) in the Biotechnology industry. This means that KNSA’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's Price Growth Rating (40) in the Biotechnology industry is in the same range as KNSA (42) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to KNSA’s over the last 12 months.

KNSA's P/E Growth Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for NTLA (100) in the Biotechnology industry. This means that KNSA’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KNSANTLA
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
66%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 6 days ago
74%
Bullish Trend 6 days ago
77%
Declines
ODDS (%)
Bearish Trend 15 days ago
80%
Bearish Trend 16 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
77%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IEGYX23.80N/A
N/A
Invesco EQV Intl Small Company Y
DEQCX15.13N/A
N/A
BNY Mellon Global Equity Income - C
MUNDX25.94N/A
N/A
Mundoval
UINQX56.21N/A
N/A
Victory Nasdaq 100 Index Institutional
ESCWX10.94N/A
N/A
Embark Small Cap Equity Institutional

KNSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with ABVC. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then ABVC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNSA
1D Price
Change %
KNSA100%
+2.53%
ABVC - KNSA
40%
Loosely correlated
-11.59%
COYA - KNSA
40%
Loosely correlated
+0.49%
CPRX - KNSA
37%
Loosely correlated
-0.87%
BEAM - KNSA
36%
Loosely correlated
+0.05%
AMRN - KNSA
36%
Loosely correlated
-4.51%
More